Prozomix与Ginkgo Bioworks合作 - Prozomix与Ginkgo Bioworks合作开发下一代酶，用于可持续API制造[1] - Prozomix加入Ginkgo Technology Network，致力于推动客户研发项目创新[2] - Prozomix和Ginkgo合作推出新一代生物催化剂，基于先前酶库的序列和活性数据[6] 生物催化剂应用需求推动 - 生物催化剂在商业API制造中的应用需求推动了行业向生物催化剂的采用[3] - 现有酶板为用户提供了在开发早期快速筛选潜在候选者的机会[4] - 生物催化剂的采用在很大程度上取决于这些板上可用酶的多样性和性能[5] 新一代酶板推出 - Prozomix打算使用由这些模型设计的下一代酶库来制造新型酶板[7] - 合作伙伴期望这些新一代酶板具有传统板缺乏的多样性和性能，可能解锁先前板失败的生物催化机会[8] 领先地位和未来展望性陈述 - Prozomix首席执行官Simon J. Charnock表示，与Ginkgo的合作将使Prozomix在AI革命中保持领先地位[9] - Ginkgo Bioworks高级总监Cindy Chang表示，API制造将大大受益于最新的酶工程和AI/ML酶模型[10] - Ginkgo Bioworks发布的新闻中提到了未来展望性陈述，这些陈述是基于当前预期和假设的，因此存在风险和不确定性[13]

Human Natural Killer cell. (National Institute of Allergy and Infectious Diseases Image)The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Boston biotech company Ginkgo Bioworks. The companies did not disclose the terms of the acquisition. An article by Fierce Biotech noted that Ginkgo’s business development team has snapped up a string of companies and assets in ...

BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries. Modulus Therapeutics Ginkgo Bioworks Acquires Modulus Therapeutics’ Cell Therapy Assets to Strengthen Next-Gen CAR Designs Modulus Therapeutics is a cell engineering company focused on the design ...

投资小盘股 - 投资者在2024年投资小盘股时，正确确定头寸大小至关重要[1] - 了解风险承受能力是关键，有助于分配适当的投资组合部分给小盘股[3] - 使用止损策略是管理交易小盘股固有风险的关键[4]

Ginkgo Bioworks (DNA 1.89%) has a lot going for it. It's a favorite of Cathie Wood's Ark Innovation ETF, it's a popular collaborator in the biopharma sector, and its positioning at the intersection of biotechnology, artificial intelligence (AI), and laboratory robotics means that it's exposed to a lot of exciting and value-enhancing developments.But does that make it a buy, or just another stock getting hyped by the tech-hungry investors of the current bull market? Here's what you need to know.Why this comp ...

LEIDEN, Netherlands , March 13, 2024 /PRNewswire/ -- ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, today announced a partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. This strategic alliance will grant Ginkgo Bioworks' customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for ...

The TGS program, a leading example of biosecurity infrastructure, operates at a total of nine US locations and leverages voluntary nasal swabs as well as wastewater sampling from international travelers to detect more than 30 pathogens. BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of o ...

Ginkgo Bioworks的发展前景 - Ginkgo Bioworks有望成为医疗行业的"七巨头"之一，其野心是颠覆新药开发方式[1] - Ginkgo Bioworks正在建立一个生物工厂，旨在为客户提供可靠高效的平台，以在即将到来的生物技术革命中竞争[6] - Ginkgo Bioworks已经与辉瑞、诺和诺德、默克、礼来和莫德纳等公司合作，运行其平台上的项目[9] Ginkgo Bioworks的业务增长 - Ginkgo Bioworks在2023年第四季度拥有162个活跃项目，较去年增长45%，2024年计划增加120个项目，预计总收入可达2.35亿美元[10] - 如果Ginkgo Bioworks能够实现自动化带来的规模经济，它可能成为类似Nvidia的关键服务提供商，从而使其股价随时间飙升，最终成为医疗行业的领先投资[8] Ginkgo Bioworks的潜在地位 - Ginkgo Bioworks有望成为生物制药领域最重要的合作伙伴之一，帮助各种规模的公司削减一些最大的成本[12] - 尽管Ginkgo Bioworks尚未必然加入医疗行业的"七巨头"，但许多成为巨头的要素目前已经存在，最后缺失的元素（希望）在其控制范围内[13]

Shares of Ginkgo Bioworks (DNA -10.53%) were sinking 9.5% lower as of 11:34 a.m. ET on Friday. The sell-off came after the biotechnology company announced its fourth-quarter and full-year 2023 results following the market close on Thursday.Ginkgo reported Q4 revenue of $34.8 million, down 65% year over year. This result was well below the Wall Street consensus estimate of $42.5 million.The company posted a fourth-quarter net loss of $211.7 million, or $0.11 per share. The average analyst estimate was for a ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2023 Earnings Conference Call February 29, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly – Co-Founder and Chief Executive Officer Mark Dmytruk – Chief Financial Officer Conference Call Participants Steve Mah – Cowen Tejas Savant – Morgan Stanley Mark Massaro – BTIG Matt Sykes – Goldman Sachs Derik de Bruin – Bank of America Matt Larew – William Blair Michael Freeman – Raymond James Megan LeDuc Good evening, I’m Megan Le ...